The Common Services Agency (more commonly known as NHS National Services Scotland) are launching a pharmaceutical framework in Edinburgh valued at £74.2 million.

This framework agreement is for the supply of unlicensed, aseptically compounded, ready to use medicines in syringe and infusion bags to NHS Scotland. this Dynamic Purchasing System is split into 4 lots:

• Lot 1:
  • Supply of the following in a range of doses: atezolizumab, cetuximab, doxorubicin, epirubicin, infliximab (inflectra®), (remicade®), (remsima®), pivolumab, pembrolizumab, pertuzumab.
• Lot 2:
  • Supply of the following in a range of doses: cyclophosphamide, fluorouracil, Iiinotecan, methotrexate, rituximab (mabthera®), (rixathon®), (truxima®).
• Lot 3:
  • Supply of the following in a range of doses: bortezomib, carboplatin, cisplatin, docetaxel, gemcitabine, oxaliplatin, trastuzumab (herceptin®), (herzuma®), vincristine.
• Lot 4:
  • Supply of the following aseptically compounded, ready to use medicines in syringes and infusions to NHS Scotland in a range of doses, the molecules included in this Lot are: bevacizumab, cytarabine, infliximab (zessly®), insulin, methotrexate, natalizumab, nivolumab, paclitaxel, pemetrexed, tocilizumab, trastuzumab (kanjinti®), (ontruzant®), trastuzumab subcutaneous, vedolizumab.
   

  Tenders can be submitted for every lot. However, successful parties can only be awarded a maximum of one of the lots .

   

  The duration of the contract is 3 years.

   

  The deadline for submission of tenders is 28 October.

   

     

  How can we help?

   

  The Bid Team’s bidding experts have many years’ experience and proven records of successfully bidding into the public sector. To find out more about our success, you can visit our case studies page. Alternatively, fill out the form below to get in touch.